鲁抗医药子公司氟哌啶醇注射液获一致性评价

财中社11-05

财中社11月5日电鲁抗医药（600789）发布关于子公司药品通过仿制药一致性评价的公告。控股子公司赛特公司收到国家药品监督管理局颁发的氟哌啶醇注射液通过一致性评价的《药品补充申请批准通知书》。该药品为注射剂，规格为1ml:5mg，原药品批准文号为国药准字 H37024042。根据药智数据，氟哌啶醇注射液在2021年至2023年期间的全国医院总销售额分别约为0.51亿元、0.54亿元和0.5亿元。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2481523447?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-05 16:11","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2481523447","market":"sh","top_or_hot":-1,"title":"鲁抗医药子公司氟哌啶醇注射液获一致性评价","media":"财中社","content":"<div>\n<p>财中社11月5日电鲁抗医药（600789）发布关于子公司药品通过仿制药一致性评价的公告。控股子公司赛特公司收到国家药品监督管理局颁发的氟哌啶醇注射液通过一致性评价的《药品补充申请批准通知书》。该药品为注射剂，规格为1ml:5mg，原药品批准文号为国药准字 H37024042。根据药智数据，氟哌啶醇注射液在2021年至2023年期间的全国医院总销售额分别约为0.51亿元、0.54亿元和0.5亿元。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105161321aba13c96&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>鲁抗医药子公司氟哌啶醇注射液获一致性评价</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n鲁抗医药子公司氟哌啶醇注射液获一致性评价\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-05 16:11 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105161321aba13c96&s=b><strong>财中社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>财中社11月5日电鲁抗医药（600789）发布关于子公司药品通过仿制药一致性评价的公告。控股子公司赛特公司收到国家药品监督管理局颁发的氟哌啶醇注射液通过一致性评价的《药品补充申请批准通知书》。该药品为注射剂，规格为1ml:5mg，原药品批准文号为国药准字 H37024042。根据药智数据，氟哌啶醇注射液在2021年至2023年期间的全国医院总销售额分别约为0.51亿元、0.54亿元和0.5亿元。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105161321aba13c96&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0046","symbol_name":"生物疫苗","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105161321aba13c96&s=b","article_id":"2481523447","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105161321aba13c96&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2481523447","pubTimestamp":1730794260,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"财中社11月5日电鲁抗医药 发布关于子公司药品通过仿制药一致性评价的公告。控股子公司赛特公司收到国家药品监督管理局颁发的氟哌啶醇注射液通过一致性评价的《药品补充申请批准通知书》。根据药智数据，氟哌啶醇注射液在2021年至2023年期间的全国医院总销售额分别约为0.51亿元、0.54亿元和0.5亿元。通过一致性评价，赛特公司提升了该药品的市场竞争力，有利于增加市场销量，并为后续产品开展仿制药一致性评价工作积累了经验。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600789":"鲁抗医药","BK0046":"生物疫苗","BK0239":"医药制造","BK0168":"禽流感","BK0188":"融资融券"},"translate_title":"Haloperidol injection, a subsidiary of Lukang Pharmaceutical, received consistency evaluation","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600789":1},"content_text":"财中社11月5日电鲁抗医药（600789）发布关于子公司药品通过仿制药一致性评价的公告。控股子公司赛特公司收到国家药品监督管理局颁发的氟哌啶醇注射液通过一致性评价的《药品补充申请批准通知书》。该药品为注射剂，规格为1ml:5mg，原药品批准文号为国药准字 H37024042。根据药智数据，氟哌啶醇注射液在2021年至2023年期间的全国医院总销售额分别约为0.51亿元、0.54亿元和0.5亿元。赛特公司在该药品的一致性评价工作中累计研发投入约为472万元（未经审计）。通过一致性评价，赛特公司提升了该药品的市场竞争力，有利于增加市场销量，并为后续产品开展仿制药一致性评价工作积累了经验。2024年前三季度，鲁抗医药实现收入46.67亿元，归母净利润3.47亿元。（文章来源：财中社）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481523447"}